SRS Capital Advisors Inc. Raises Stake in Amedisys, Inc. (NASDAQ:AMED)

SRS Capital Advisors Inc. lifted its position in shares of Amedisys, Inc. (NASDAQ:AMED) by 2,298.2% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 1,319 shares of the health services provider’s stock after buying an additional 1,264 shares during the period. SRS Capital Advisors Inc.’s holdings in Amedisys were worth $120,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Blue Trust Inc. lifted its stake in shares of Amedisys by 55.1% during the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock worth $34,000 after purchasing an additional 124 shares during the period. HBW Advisory Services LLC acquired a new stake in Amedisys in the 4th quarter worth about $38,000. Versant Capital Management Inc grew its holdings in Amedisys by 68.5% in the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock valued at $41,000 after buying an additional 183 shares during the period. KBC Group NV acquired a new position in shares of Amedisys during the 3rd quarter valued at about $63,000. Finally, Venturi Wealth Management LLC lifted its holdings in shares of Amedisys by 397.4% during the 4th quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider’s stock worth $89,000 after acquiring an additional 779 shares during the period. 94.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Stephens restated an “equal weight” rating and issued a $101.00 target price on shares of Amedisys in a report on Tuesday. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $100.75.

Amedisys Stock Down 0.1 %

AMED opened at $92.03 on Thursday. The company has a market cap of $3.01 billion, a PE ratio of 36.52, a price-to-earnings-growth ratio of 1.78 and a beta of 0.73. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. Amedisys, Inc. has a 1 year low of $82.15 and a 1 year high of $98.95. The firm has a 50 day moving average price of $91.69 and a 200 day moving average price of $93.06.

Amedisys (NASDAQ:AMED) last issued its earnings results on Wednesday, February 26th. The health services provider reported $0.96 EPS for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The business had revenue of $598.05 million during the quarter, compared to analysts’ expectations of $602.38 million. Sell-side analysts expect that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.